Prosight Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-398,700
| Closed | -$2.46M | – | 44 |
|
|
2024
Q2 | $2.46M | Sell |
398,700
-1,001,300
| -72% | -$6.19M | 0.74% | 28 |
|
|
2024
Q1 | $7.11M | Sell |
1,400,000
-832,242
| -37% | -$4.23M | 1.98% | 16 |
|
|
2023
Q4 | $13.4M | Sell |
2,232,242
-175,893
| -7% | -$1.05M | 5.37% | 7 |
|
|
2023
Q3 | $17M | Sell |
2,408,135
-91,865
| -4% | -$650K | 5.4% | 6 |
|
|
2023
Q2 | $17.6M | Buy |
2,500,000
+1,425,407
| +133% | +$10M | 5.15% | 5 |
|
|
2023
Q1 | $8.96M | Buy |
1,074,593
+957,861
| +821% | +$7.99M | 4.25% | 7 |
|
|
2022
Q4 | $1.34M | Buy |
116,732
+2,932
| +3% | +$33.7K | 0.73% | 27 |
|
|
2022
Q3 | $1.43M | Sell |
113,800
-62,880
| -36% | -$792K | 0.77% | 26 |
|
|
2022
Q2 | $1.87M | Buy |
+176,680
| New | +$1.87M | 1.47% | 17 |
|